Aerpio Pharmaceuticals (OTCMKTS:ARPO) Lowered to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Aerpio Pharmaceuticals (OTCMKTS:ARPO) from a buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company’ product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. “

Separately, HC Wainwright reiterated a hold rating and issued a $1.00 price target on shares of Aerpio Pharmaceuticals in a research note on Friday, August 9th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $5.00.

OTCMKTS:ARPO opened at $0.62 on Tuesday. Aerpio Pharmaceuticals has a one year low of $0.61 and a one year high of $4.25. The business’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.51.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.04.

A number of hedge funds and other institutional investors have recently made changes to their positions in ARPO. Vanguard Group Inc. raised its stake in Aerpio Pharmaceuticals by 9.1% during the second quarter. Vanguard Group Inc. now owns 1,300,889 shares of the company’s stock valued at $1,183,000 after buying an additional 108,749 shares in the last quarter. Alambic Investment Management L.P. acquired a new stake in Aerpio Pharmaceuticals during the first quarter valued at approximately $85,000. BlackRock Inc. raised its stake in Aerpio Pharmaceuticals by 78.8% during the second quarter. BlackRock Inc. now owns 165,222 shares of the company’s stock valued at $150,000 after buying an additional 72,796 shares in the last quarter. Jane Street Group LLC raised its stake in Aerpio Pharmaceuticals by 216.3% during the fourth quarter. Jane Street Group LLC now owns 81,984 shares of the company’s stock valued at $139,000 after buying an additional 56,065 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its stake in Aerpio Pharmaceuticals by 390.2% during the second quarter. Panagora Asset Management Inc. now owns 64,074 shares of the company’s stock valued at $58,000 after buying an additional 51,003 shares in the last quarter. Hedge funds and other institutional investors own 0.37% of the company’s stock.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Featured Article: Short Selling

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Reduces Position in Capri Holdings Ltd
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Buys 435 Shares of Allstate Corp
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
Meeder Asset Management Inc. Reduces Stock Holdings in Helmerich & Payne, Inc.
SBA Communications Co.  Shares Sold by Meeder Asset Management Inc.
SBA Communications Co. Shares Sold by Meeder Asset Management Inc.
Cactus Inc  Position Increased by Meeder Asset Management Inc.
Cactus Inc Position Increased by Meeder Asset Management Inc.
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA
Meeder Asset Management Inc. Purchases 622 Shares of Zions Bancorporation NA


© 2006-2019 Ticker Report